Health Care Services

Hims & Hers Health

Canaccord Genuity: FDA Review May Boost Hims & Hers Market Share, Potential Market Reaches $20B

Hims & Hers Health Amends Credit Agreement to Facilitate Eucalyptus Acquisition

Hims & Hers Completes Acquisition of Eucalyptus to Accelerate Canadian Healthcare Transformation

Hims & Hers Acquires Eucalyptus Parent to Enter Japanese Market

Hims & Hers Completes Acquisition of Eucalyptus to Expand German Weight Management Care

Hims & Hers Completes Acquisition of Eucalyptus to Enter Japan Market

Hims & Hers Health Expands Benefits Program, Stock Trades 61.8% Below Fair Value

Bank of America lowers Hims & Hers Health price target to $25, maintains neutral rating

Hims & Hers Health Director David B. Wells Invests $1.17M to Buy Nearly 50k Shares

Hims & Hers Health Launches Generic Semaglutide in Canada

Hims & Hers Health CFO Oluyemi Okupe Sells Nearly 8,000 Shares

Bank of America Lowers Hims & Hers Price Target to $28 from $30

Hims & Hers Health Increases Convertible Note Offering to $350 Million

Hims & Hers debuts first AI agent, Labs AI

Hims & Hers Health Reports Net Loss in Q1 2026 Results, Leading to Stock Volatility

Law Firm Investigates Hims & Hers Health for Potential Corporate Wrongdoing

Hims & Hers Health expects to close its acquisition of Eucalyptus in mid-2026.

Investment group Susquehanna discloses a 6.5% passive stake in Hims & Hers

Hims & Hers reports Q1 earnings with an unexpected loss of $0.40 per share, but raises full-year revenue forecast

Capital World Investors discloses its stake in Hims & Hers

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

Hims & Hers Health, Inc. (HIMS.US) Q1 2026 Earnings Conference Call

Hims & Hers Health, Inc. (HIMS.US) Q4 2025 Earnings Conference Call

Hims & Hers Health, Inc. (HIMS.US) Q3 2025 Earnings Conference Call

Hims & Hers Health, Inc. (HIMS.US) Q2 2025 Earnings Conference Call

HIMS

HIMY

HIMZ

Hims & Hers Health (NYSE: HIMS) shares rose 1.91% to $27.69, driven by the appointment of Anant Vinjamoori as chief medical officer and positive sentiment in healthcare stocks. Technically, the stock shows improving momentum with MACD signals but remains below its 200-day SMA, facing resistance at $30.50.

benzinga_article

Defiance Leveraged Long +Income HIMS ETF

Defiance Daily Target 2X Long HIMS ETF

S&P 500

SPDR S&P 500

Dow Jones Industrial Average

SPDR Djia

AmpliTech

Vail Resorts

Mission Produce

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)

Hims & Hers Stock Edges Higher: What's Going On?

On June 8, Eastern Time, Hims & Hers Health options saw a total of 79737 contracts traded, with calls accounting for 74% and puts making up 25%.

Options Flow

Trending | HIMS Increases 3% on Monday, Some Call options Increases 33%

Hims & Hers Health (NYSE: HIMS) is expanding its healthcare platform via GLP-1 demand and international growth, despite recent stock drops and margin pressures. While long-term upside exists if cross-selling succeeds, Motley Fool's Stock Advisor did not include HIMS in its current top 10 buy recommendations, favoring other stocks with higher potential returns.

nasdaq

NVIDIA

Intel

Netflix

Nasdaq

NVIDIA Corporation

Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock

Hims & Hers Health (NYSE: HIMS) shares rose 7.23% to $29.50 following the appointment of Anant Vinjamoori as chief medical officer, highlighting his expertise in longevity and preventive care. While short-term momentum indicators show improvement with the stock trading above key short-term moving averages, the longer-term trend remains bearish due to a 'death cross' and significant year-to-date decline. Key technical levels include resistance at $30.50 and support at $28.00.

Redwire

Momentus

MOMENTUS INC C/WTS 12/08/2026 (TO PUR COM)

Hims & Hers Stock Jumps: What's Happening Today?

ALGN

Benzinga tracked significant options activity in the Health Care sector, highlighting 'whale' trades for stocks including NVO, PURR, ALGN, LEGN, HIMS, ISRG, UNH, LLY, WGS, and JNJ. The data details specific put/call sweeps and trades, noting sentiments ranging from bearish to bullish and neutral, along with expiration dates, strike prices, and volume metrics to identify potential trading opportunities.

GeneDx

Align

Unitedhealth

Novo Nordisk AS

Legend Biotech

Johnson & Johnson

Eli Lilly

Intuitive Surgical

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Short LLY ETF

Defiance Daily Target 2X Long NVO ETF

Direxion Daily LLY Bear 1X Shares

Defiance Daily Target 2X Long LLY ETF

Leverage Shares 2X Long UNH Daily ETF

GraniteShares 2x Long ISRG Daily ETF

Hyperliquid Strategies

GeneDx - CW27

10 Health Care Stocks Whale Activity In Today's Session

Hims & Hers Health completed its acquisition of Eucalyptus, expanding operations into Australia, Japan, Germany, Canada, and the UK. This move transitions the company from a US-centric model to a global digital health platform with established local infrastructure. While the stock trades slightly above analyst targets, it is valued significantly below fair value estimates. Investors are advised to monitor integration progress, regulatory compliance, and capital allocation as the company diversifies geographically.

Simplywall

Hims And Hers Expands Globally With Eucalyptus Deal And Valuation Gap

Hims & Hers Health amended its revolving credit agreement with JPMorgan to facilitate the acquisition of Eucalyptus. The amendment introduces a post-closing grace period for covenant compliance, adds joinder obligations for material foreign subsidiaries, and increases capacity for downstream investments in non-loan party subsidiaries. Other terms remain largely unchanged.

TradingView

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Hims & Hers Amends Revolving Credit Agreement With JPMorgan to Support Eucalyptus Deal

Hims & Hers Health(HIMS.US)